Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A nutritional combination consisting of isomaltulose, a low-glycemic disaccharide, and resistant dextrin, a soluble prebiotic fiber. This combination is typically studied as a functional food ingredient or supplement to improve glycemic control and insulin sensitivity. Isomaltulose (alpha-1,6-linked glucose and fructose) provides a slower, more sustained release of glucose compared to sucrose or maltose, resulting in a lower glycemic index. Resistant dextrin acts as a prebiotic fiber that may improve insulin resistance and promote satiety through gut microbiota modulation. In clinical research, this combination has been incorporated into alcohol-free beer to mitigate the high glycemic impact of traditional maltose-heavy beverages, demonstrating significant reductions in insulin concentrations and HOMA-IR in overweight or obese patients with type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isomaltulose + resistant dextrin.